Specderm Poznanska Sp. j.
- Address
- lock Available on a paid plan
Specderm Poznanska Sp. j. - Specialized Dermatology Research Center
Specderm Poznanska Sp. j. is a distinguished clinical research facility specializing in dermatological conditions and inflammatory skin diseases. The center has established particular expertise in evaluating novel biologic therapies and topical treatments across a diverse spectrum of dermatological disorders, ranging from common inflammatory conditions to complex autoimmune skin manifestations.
- Moderate to severe plaque psoriasis and psoriatic arthritis, including studies of advanced biologics and immune-modulating agents
- Acne vulgaris treatment development with novel topical formulations and long-term safety evaluation
- Specialized dermatological conditions including nonsegmental vitiligo, chronic hand eczema, and recurrent herpes labialis
- Comparative effectiveness research and pharmacokinetic studies in both adult and adolescent populations
The research center demonstrates comprehensive capabilities in conducting Phase 3 placebo-controlled trials and long-term extension studies, with particular strength in evaluating innovative therapies such as JAK inhibitors and IL-17/IL-23 pathway modulators. Their portfolio also extends beyond dermatology to include metabolic conditions like Type 2 diabetes, reflecting a multidisciplinary approach to clinical research. The facility's experience encompasses both efficacy and safety assessments, including studies comparing novel agents to established active comparators and vehicle controls.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 22 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Eli Lilly & Co.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specderm Poznanska Sp. j.
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Deucravacitinib in Adolescent Subjects (12 years to less than 18 years) with Moderate to Severe Plaque Psoriasis | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 22 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Jnj-77242113 | 5 | Unknown | 2023-12-05 | 2025-05-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.